Compare GSK plc (GSK) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Magnificent Seven ETF — how do they compare? GSK plc trades at $52.58 (market cap $101.34B), while Roundhill Magnificent Seven ETF trades at $68.85. The key difference: GSK plc pays a 3.49% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | MAGS | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $70.94 |
52-Week Low | $36.20 | $55.39 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
MAGS (Roundhill Magnificent Seven ETF) trades at $68.76, up 1.96% with a bullish technical signal from moving averages but overbought RSI readings. The ETF holds seven mega-cap tech stocks equally weighted, benefiting from AI-driven momentum but facing high concentration risk. Recent news highlights AI spending shifts from chipmakers to hyperscalers, with MAGS mentioned as a key vehicle for Magnificent Seven exposure.
Outlook remains positive due to AI infrastructure growth, but valuations are compressed for hyperscalers like Amazon and Microsoft. Risks include reliance on tech sector performance and potential rotation to small-caps. Analyst sentiment is mixed, with some seeing upside as AI revenues outpace capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
